—
C+
C+ The full Closelooknet — membership. Open the C+ overview

AstraZeneca PLC (AZN) — chart, structure and Closelooknet read

The Closelooknet read

AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, vaccines, and rare diseases. It sells through distributors and its own representative offices across the UK, the United States, Europe, Asia, Africa and Australasia.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on AZN

What this diary said about AstraZeneca PLC, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we said

Signals for this name

Every Closelooknet reading that exists for AZN, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 6 pieces · newest: Midday 10, “Sell-Off — Nasdaq −3%, Chips −8%, Bitcoin −4%, Gold −3%; Only Bonds, Oil and Defensives Hold” (2026-10-30)

Mentioned on Closelooknet

Where AZN appears in the diary — 6 pieces, newest first. Every link is our own writing.

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-30
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 81th percentile of the window, -13.7% over 20 sessions. Factor regime → 2026-10-29
  • Sovereign pressure Index -1.66 · down 2.24 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-30
How it trades on rate days beta 0.93 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How AZN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.93 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), AstraZeneca PLC moved 0.93% on average · correlation 0.32 · higher than 80% of US names
  • Beta, last 3 months 1.17 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.78% on average against −0.74% for the S&P 500 the 8 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.75% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against AZN on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — AstraZeneca PLC

AZN in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, vaccines, and rare diseases. It sells through distributors and its own representative offices across the UK, the United States, Europe, Asia, Africa and Australasia. It is based in Cambridge, England.
Where it sits in the stack
AstraZeneca sits in the Research, Design & Development section of our AI Users index, which tracks companies applying AI inside an existing business rather than building the AI stack itself. By February 2025 it said AI supports most of its small-molecule drug programmes from target to clinic, lifted output and cut lead time at its Wuxi manufacturing site, and reads a growing volume of chest x-rays for early lung-nodule screening. In each case the AI assists scientists and staff rather than acting on its own.
Who it is priced against
Closelooknet's peer group places it with the broad drug manufacturers, including Amgen, GSK, AbbVie, Pfizer, Gilead, Johnson & Johnson, Merck and Bristol-Myers Squibb; the market also names Novartis as a comparator.
Why Closelooknet tracks it
AstraZeneca holds a Research, Design & Development seat in our AI Users index but carries no Closelooknet score, so its peer group is ranked on trend state rather than a score. The diary's Pattern Scanner has repeatedly flagged it among active support-confluence signals in yellow regime across several Daily Pulse editions.
What the diary watches
Whether the stated plan to screen five million patients for lung-cancer risk with AI, and the iLab goal of halving candidate-identification time, show up in slower programme timelines or wider screening volumes as those plans mature.

AstraZeneca PLC (AZN) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-10-25. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: initiation by RBC Capital, 2026-09-08

The Street on this name

Analyst actions and the latest print for AZN from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation RBC Capital — at Outperform Initiated to Outperform 2026-09-08
  • Initiation CICC — at Outperform Initiated to Outperform 2026-08-23

2 actions on the analyst wire since 2026-08-13: 2 initiations. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 1.73%, semi-annual · last 1.06 USD on 2026-08-06

Dividends and capital return

What AZN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 3.23 USD per share · a 1.73% yield on the 2026-10-30 close 2 distributions, paid twice a year 2026-10-30
  • Last distribution 1.06 USD per share as the price series records it, within days of the ex-date 2026-08-06
  • By calendar year 2026: 3.23 USD to date first distribution recorded in the three-year window: 2026-02-20

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-31

Quick answers

What is AstraZeneca PLC (AZN)?

AstraZeneca PLC trades as AZN on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-31.

Is AZN in a Closelooknet index?

Not currently — AstraZeneca PLC is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-31.

How does AstraZeneca PLC trade when bond yields rise?

Over the past year AstraZeneca PLC had a beta of 0.93 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 80% of US names. On the 8 sessions in which long bonds fell most it moved −0.78% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about AstraZeneca PLC?

AstraZeneca PLC appears in 6 Closelooknet pieces, most recently Midday 10: Sell-Off — Nasdaq −3%, Chips −8%, Bitcoin −4%, Gold −3%; Only Bonds, Oil and Defensives Hold (2026-10-30); Daily Pulse: Friday flips broadly risk-off — Korea −6.1%, Temperature still 57 (2026-05-18); Daily Pulse: Temperature 61 — semis overheating into the catalyst window (2026-05-12). What Closelooknet said most recently: What holds: the 10-year Treasury yield eases to 4.94%, oil rises 2.0%, and staples, energy, utilities and health care gain, with Accenture up 4.9%, Eli Lilly 3.2% and AstraZeneca 7.4%. (Midday 10, 2026-10-30). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does AstraZeneca PLC do?

AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, vaccines, and rare diseases. It sells through distributors and its own representative offices across the UK, the United States, Europe, Asia, Africa and Australasia. It is based in Cambridge, England. Closelooknet's peer group places it with the broad drug manufacturers, including Amgen, GSK, AbbVie, Pfizer, Gilead, Johnson & Johnson, Merck and Bristol-Myers Squibb; the market also names Novartis as a comparator.

Where does AstraZeneca PLC sit in the AI build-out?

AstraZeneca sits in the Research, Design & Development section of our AI Users index, which tracks companies applying AI inside an existing business rather than building the AI stack itself. By February 2025 it said AI supports most of its small-molecule drug programmes from target to clinic, lifted output and cut lead time at its Wuxi manufacturing site, and reads a growing volume of chest x-rays for early lung-nodule screening. In each case the AI assists scientists and staff rather than acting on its own. AstraZeneca holds a Research, Design & Development seat in our AI Users index but carries no Closelooknet score, so its peer group is ranked on trend state rather than a score. The diary's Pattern Scanner has repeatedly flagged it among active support-confluence signals in yellow regime across several Daily Pulse editions.

Does AstraZeneca PLC pay a dividend?

AstraZeneca PLC has paid 3.23 USD per share over the last twelve months, paid twice a year, a trailing yield of 1.73% on the 2026-10-30 close; the last distribution recorded in the price series was 1.06 USD on 2026-08-06. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on AstraZeneca PLC recently?

The most recent analyst action on AstraZeneca PLC on the Closelooknet wire is a initiation by RBC Capital on 2026-09-08 (at Outperform). 2 actions on the analyst wire since 2026-08-13: 2 initiations. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for AZN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.